82 FR 11475 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 35 (February 23, 2017)

Page Range		11475-11476
FR Document		2017-03531

Federal Register, Volume 82 Issue 35 (Thursday, February 23, 2017)

[Federal Register Volume 82, Number 35 (Thursday, February 23, 2017)]
[Notices]
[Pages 11475-11476]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03531]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel, Elucidation of Mechanisms of 
Radiation-Induced Endovascular Injury and Development of Treatments/
Mitigators for Radiation-Induced Endothelial Cell and Vascular 
Dysfunction (U01).
    Date: March 16-17, 2017.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892, (Telephone Conference Call).
    Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural

[[Page 11476]]

Activities, Room # 3G41B, National Institutes of Health/NIAID, 5601 
Fishers Lane, MSC9823, Bethesda, MD 20892-9823, (240) 669-5068, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: February 17, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03531 Filed 2-22-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 35 / Thursday, February 23, 2017 / Notices 11475

Place: National Institutes of Health, 6701 301–496–2644. A signed Confidential alters signaling to drive cytokine
Rockledge Drive, Bethesda, MD 20892, Disclosure Agreement will be required responses that enhance septic shock.’’
(Telephone Conference Call). to receive copies of unpublished patent Immunity 44.6 (2016): 1365–1378.
Contact Person: Syed M Quadri, Ph.D.,
Scientific Review Officer, Center for
applications. Intellectual Property: HHS Reference
Scientific Review, National Institutes of SUPPLEMENTARY INFORMATION: No. E–112–2016/0—U.S. Patent
Health, 6701 Rockledge Drive, Room 6210, Technology description follows. Application No. 62/308,144 filed 03/14/
MSC 7804, Bethesda, MD 20892, 301–435– 2016.
1211, quadris@csr.nih.gov. CD300b Expression Exacerbates Licensing Contact: Chris Kornak, 240–
Name of Committee: Center for Scientific
Endotoxemia and Septic Peritonitis 627–3705, chris.kornak@nih.gov.
Review Special Emphasis Panel; Member Description of Technology: The innate Collaborative Research Opportunity:
Conflict: Emerging Technologies in immune system is the first line of host The National Institute of Allergy and
Neuroscience. defense against invading pathogens. Infectious Diseases is seeking statements
Date: March 24, 2017. Lipopolysaccharides (LPS), present in of capability or interest from parties
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant gram-negative bacteria membranes, interested in collaborative research to
applications. cause strong immune responses further co-develop CD300b antagonists.
Place: National Institutes of Health, 6701 following detection by the Toll-like For collaboration opportunities, please
Rockledge Drive, Bethesda, MD 20892, receptor 4 (TLR4) on immune cells. This contact Chris Kornak, 240–627–3705,
(Virtual Meeting). detection results in the release of pro- chris.kornak@nih.gov.
Contact Person: Sharon S Low, Ph.D., inflammatory cytokines, such as tumor Dated: February 16, 2017.
Scientific Review Officer, Center for necrosis factor alpha, interleukin-6, and
Scientific Review, National Institutes of Suzanne Frisbie,
interferon gamma, to assist with
Health, 6701 Rockledge Drive, Room 5104, Deputy Director, Technology Transfer and
MSC 5104, Bethesda, MD 20892–5104, 301–
clearance of the infectious insult. In Intellectual Property Office, National Institute
237–1487, lowss@csr.nih.gov. parallel, interleukin-10 (IL–10), an anti- of Allergy and Infectious Diseases.
(Catalogue of Federal Domestic Assistance inflammatory cytokine, is induced to [FR Doc. 2017–03452 Filed 2–22–17; 8:45 am]
Program Nos. 93.306, Comparative Medicine; limit the immune response. This is
BILLING CODE 4140–01–P
93.333, Clinical Research, 93.306, 93.333, because unchecked immune activation
93.337, 93.393–93.396, 93.837–93.844, leads to a more severe
93.846–93.878, 93.892, 93.893, National immunopathology, such as septic shock DEPARTMENT OF HEALTH AND
Institutes of Health, HHS) and subsequently death. Current HUMAN SERVICES
Dated: February 17, 2017. therapies to treat sepsis are ineffective,
Anna Snouffer, and clinical trials based on National Institutes of Health
Deputy Director, Office of Federal Advisory neutralization of specific inflammatory
Committee Policy. cytokines have failed. National Institute of Allergy and
[FR Doc. 2017–03528 Filed 2–22–17; 8:45 am]
The inventors, listed below, have Infectious Diseases; Notice of Closed
discovered that CD300b is a LPS Meeting
BILLING CODE 4140–01–P
binding receptor. This interaction
Pursuant to section 10(d) of the
results in a reduced IL–10 production,
Federal Advisory Committee Act, as
DEPARTMENT OF HEALTH AND leading to an amplification of lethal
amended (5 U.S.C. App.), notice is
HUMAN SERVICES inflammation. In vitro, anti-CD300b
hereby given of the following meeting.
antibodies block LPS binding to
The meeting will be closed to the
National Institutes of Health CD300b, stopping association with
public in accordance with the
TLR4 and CD14 and increases IL–10
Government-Owned Inventions; provisions set forth in sections
levels. In vivo, administration of anti-
Availability for Licensing 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
CD300b antibodies protects animals
as amended. The grant applications and
AGENCY: National Institutes of Health, from septic shock, due to a reduce level
the discussions could disclose
HHS. of pro-inflammatory cytokines but
confidential trade secrets or commercial
subsequent increase in the anti-
ACTION: Notice. property such as patentable material,
inflammatory cytokine, IL–10.
This technology is available for and personal information concerning
SUMMARY: The invention listed below is individuals associated with the grant
owned by an agency of the U.S. licensing for commercial development
in accordance with 35 U.S.C. 209 and 37 applications, the disclosure of which
Government and is available for would constitute a clearly unwarranted
licensing to achieve expeditious CFR part 404, as well as for further
development and evaluation under a invasion of personal privacy.
commercialization of results of
federally-funded research and research collaboration. Name of Committee: National Institute of
development. Foreign patent Potential Commercial Applications: Allergy and Infectious Diseases Special
As a means of treating endotoxemia and Emphasis Panel, Elucidation of Mechanisms
applications are filed on selected of Radiation-Induced Endovascular Injury
inventions to extend market coverage septic peritonitis.
and Development of Treatments/Mitigators
for companies and may also be available Competitive Advantages: No current
for Radiation-Induced Endothelial Cell and
for licensing. therapeutics are available to treat septic Vascular Dysfunction (U01).
FOR FURTHER INFORMATION CONTACT: shock. Date: March 16–17, 2017.
Licensing information and copies of the Development Stage: Pre-clinical. Time: 10:00 a.m. to 5:00 p.m.
rmajette on DSK2TPTVN1PROD with NOTICES

patent applications listed below may be Inventors: Agenda: To review and evaluate grant
obtained by communicating with the John E. Coligan, NIAID, NIH applications.
Oliver H. Voss, NIAID, NIH Place: National Institutes of Health, 5601
indicated licensing contact at the Fishers Lane, Rockville, MD 20892,
Technology Transfer and Intellectual Konrad Krzewski, NIAID, NIH
(Telephone Conference Call).
Property Office, National Institute of Publications: Voss, Oliver H., et al. Contact Person: Zhuqing (Charlie) Li,
Allergy and Infectious Diseases, 5601 ‘‘Lipopolysaccharide-induced CD300b Ph.D., Scientific Review Officer, Scientific
Fishers Lane, Rockville, MD, 20852; tel. receptor binding to toll-like receptor 4 Review Program, Division of Extramural

VerDate Sep<11>2014 14:10 Feb 22, 2017 Jkt 241001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\23FEN1.SGM 23FEN1

Document Created: 2017-02-23 02:10:45
Document Modified: 2017-02-23 02:10:45

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		March 16-17, 2017.
FR Citation		82 FR 11475

82 FR 11475 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 35 (February 23, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health